EpiVax, Inc., a Providence, RI-based immune engineering company, has won a new $600k National Institutes of Health grant.
The grant was awarded under the Small Business Innovation Research (SBIR) program to improve a vaccine for the problematic H7N9 avian influenza virus.
Led by Dr. Anne S. De Groot, M.D., and Bill Martin, EpiVax develops vaccines and immunotherapies for infectious diseases, autoimmunity and cancer. The vaccine development program will be directed by Annie De Groot, M.D., EpiVax CEO/CSO, and Lenny Moise, Ph.D., EpiVax Director of Vaccine Research, and carried out in collaboration with Ted Ross, Ph.D., Professor, Department of Infectious Diseases, and Director, Center for Vaccines and Immunology, University of Georgia.
The first version of the optimized influenza vaccine designed by EpiVax will soon enter a Phase I trial in Australia, in collaboration with Vaxine and Protein Sciences Corporation.